Evidence map›Paper›PMID 37955203›Full record

ArticleJournal of materials chemistry. B2023

Polymer-prodrug conjugates as candidates for degradable, long-acting implants, releasing the water-soluble nucleoside reverse-transcriptase inhibitor emtricitabine.

Chung Liu, Faye Y Hern, Anika Shakil, Kartik Temburnikar, Pierre Chambon, Neill Liptrott, Tom O McDonald, Megan Neary, Charles Flexner, Andrew Owen and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of materials chemistry. B, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Chung LiuDepartment of Chemistry, University of Liverpool, Crown Street, Liverpool, L69 7ZD, UK. srannard@liverpool.ac.uk.
Faye Y HernDepartment of Chemistry, University of Liverpool, Crown Street, Liverpool, L69 7ZD, UK. srannard@liverpool.ac.uk.
Anika ShakilDepartment of Chemistry, University of Liverpool, Crown Street, Liverpool, L69 7ZD, UK. srannard@liverpool.ac.uk.
Kartik TemburnikarDepartment of Pharmacology and Molecular Sciences, The Johns Hopkins University School of Medicine, 725 North Wolfe St., Baltimore, MD, 21205, USA.
Pierre ChambonDepartment of Chemistry, University of Liverpool, Crown Street, Liverpool, L69 7ZD, UK. srannard@liverpool.ac.uk.
Neill LiptrottCentre of Excellence in Long-acting Therapeutics (CELT), University of Liverpool, Liverpool, L7 3NY, UK.ORCID 0000-0002-5980-8966
Tom O McDonaldDepartment of Chemistry, University of Liverpool, Crown Street, Liverpool, L69 7ZD, UK. srannard@liverpool.ac.uk.ORCID 0000-0002-9273-9173
Megan NearyMaterials Innovation Factory, University of Liverpool, Crown Street, L69 7ZD, UK.
Charles FlexnerDepartment of Pharmacology and Molecular Sciences, The Johns Hopkins University School of Medicine, 725 North Wolfe St., Baltimore, MD, 21205, USA.
Andrew OwenMaterials Innovation Factory, University of Liverpool, Crown Street, L69 7ZD, UK.
Caren Freel MeyersDepartment of Pharmacology and Molecular Sciences, The Johns Hopkins University School of Medicine, 725 North Wolfe St., Baltimore, MD, 21205, USA.
Steve P RannardDepartment of Chemistry, University of Liverpool, Crown Street, Liverpool, L69 7ZD, UK. srannard@liverpool.ac.uk.ORCID 0000-0002-6946-1097

Funding

Long acting NRTI therapies for HIVR01AI134091 · NIAID · JOHNS HOPKINS UNIVERSITY · PI FREEL MEYERS, CAREN L., RANNARD, STEVE · 2017 to 2021
$3.1M
NIAID NIH HHS R01 AI134091
6 · The paper itself

Abstract

Circulating, soluble polymer-drug conjugates have been utilised for many years to aid the delivery of sensitive, poorly-soluble or cytotoxic drugs, prolong circulation times or minimise side effects. Long-acting therapeutics are increasing in their healthcare importance, with intramuscular and subcutaneous administration of liquid formulations being most common. Degradable implants also offer opportunities and the use of polymer-prodrug conjugates as implant materials has not been widely reported in this context. Here, the potential for polymer-prodrug conjugates of the water soluble nucleoside reverse transciption inhibitor emtricitabine (FTC) is studied. A novel diol monomer scaffold, allowing variation of prodrug substitution, has been used to form polyesters and polycarbonates by step-growth polymerisation. Materials have been screened for physical properties that enable implant formation, studied for drug release to provide mechanistic insights, and tunable prolonged release of FTC has been demonstrated over a period of at least two weeks under relevant physiological conditions.

Indexed as

ProdrugsDNA-Directed RNA PolymerasesEmtricitabineNucleosidesPolymersWaterDNA-Directed RNA PolymerasesEmtricitabineNucleosidesPolymersProdrugsWater

Identifiers

PMID37955203
PMCPMC10718295

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.